Chong Kun Dang’s candidate COVID-19 treatment Nafabeltan has failed to get the South Korean health authority’s conditional approval.

As the Ministry of Food and Drug Safety (MFDS) shut the first door of conditional approval to highly anticipated candidate Nafabeltan, the public is now curious of who would be the next second South Korean-made COVID-19 treatment.

Currently, the public highly anticipates of GC Pharma’s investigative plasma treatment. Also the anticipation on Bukwang Pharm, Daewoong Pharmaceutical and Shin Poong Pharm are heightening as well.

◆MFDS “Needs additional clinical trial,” Chong Kun Dang “Phase III clinical trial planned”

Kim, Jin-Gu(kjg@dailypharm.com)